Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat-dose intranasal GSK256066 in Vienna Challenge Chamber for seasonal allergic rhinitis
2006-006000-11Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GSK256066 in seasonal allergic rhinitis (SAR) (2 arms), sponsored by GSK. Primary endpoint: Weighted mean total nasal symptom score 1–4 hours post-dose on Day 7. Started Nov 2006; status: completed.
02
Drugs
GSK256066
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2006-006000-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006000-11.